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Abstract
Wildlife reservoirs of Mycobacterium bovis represent serious obstacles to the eradication of tuberculosis in domestic livestock. In Michigan,
USA tuberculous white-tailed deer transmit M. bovis to cattle. One approach in dealing with this wildlife reservoir is to vaccinate deer in order
to interrupt the cycle of deer to deer and deer to cattle transmission. Thirty-one white-tailed deer were assigned to one of three groups; 2 SC
doses of 107 CFU of M. bovis BCG (n = 11); 1 SC dose of 107 CFU of M. bovis BCG (n = 10); or unvaccinated deer (n = 10). After vaccination,
deer were inoculated intratonsilarly with 300 CFU of virulent M. bovis. Gross lesion severity scores of the medial retropharyngeal lymph
node were significantly reduced in deer receiving 2 doses of BCG compared to unvaccinated deer. Vaccinated deer had fewer lymph node
granulomas than unvaccinated deer, and most notably, fewer late stage granulomas characterized by coalescent caseonecrotic granulomas
containing numerous acid-fast bacilli. BCG was isolated from 7/21 vaccinated deer as long as 249 days after vaccination. In one case BCG
was transmitted from a vaccinated deer to an unvaccinated deer. In white-tailed deer BCG provides measurable protection against challenge
with virulent M. bovis. However, persistence of vaccine within tissues as well as shedding of BCG from vaccinates remain areas for further
investigation.
Published by Elsevier Ltd.
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1. Introduction
In 1994, a free-ranging white-tailed deer (Odocoileus vir-
ginianus) in Michigan was diagnosed with tuberculosis due
to Mycobacterium bovis, the causative agent of bovine tuber-
culosis [1]. Subsequent surveys identified a focus of M. bovis
infection in free-ranging white-tailed deer in northeast Michi-
gan [2,3]. This represents the first known reservoir of M. bovis
in free-ranging wildlife in the United States and a significant
obstacle to the eradication of bovine tuberculosis in domestic
livestock. Several factors are thought to have contributed to
the establishment and persistence of M. bovis in this wildlife
reservoir. It is postulated that M. bovis was transmitted from
cattle to deer at some time during the mid 1900s when a
∗ Corresponding author. Tel.: +1 515 663 7474; fax: +1 515 663 7458.
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large number of Michigan cattle were infected with M. bovis
[4]. During this same period, Michigan’s deer population was
steadily increasing beyond normal habitat carrying capacity
to focal concentrations of 19–23 deer/km2 [1]. Transmission
and maintenance of M. bovis among deer is thought to have
been facilitated by the common practice in Michigan of long-
term winter feeding of deer by private citizens to prevent
migration and decrease winter mortality in order to keep deer
numbers high for hunting purposes [1].
Current disease control measures in Michigan include
decreasing deer density through increased hunting and strict
control of feeding and baiting of white-tailed deer. Another
possible control measure could be vaccination of white-tailed
deer to prevent infection, disease, or transmission. Vaccina-
tion of captive farmed red deer in New Zealand has shown
that vaccination with M. bovis BCG can prevent infection
and disease (i.e. lesion development) [5,6]. BCG vaccination
0264-410X/$ – see front matter. Published by Elsevier Ltd.
doi:10.1016/j.vaccine.2007.06.056
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has also been used to control tuberculosis in farmed sika deer
(Cervus nippon) in China [7].
M. bovis BCG was first used as an anti-tuberculosis vac-
cine in humans in 1921 and is one of the oldest and most
widely used vaccines in the world today [8]. Although reports
of efficacy in humans vary widely by geographic region
and among different age groups, consistent protection has
been observed against miliary tuberculosis and tuberculous
meningitis when used as a single dose in neonates. The great
variability in efficacy is often attributed to one or more factors
including, differences in vaccines strains, prior host sensitiza-
tion to various non-tuberculous environmental mycobacteria,
genetic differences in trial populations, or trial design [8].
Protection against M. bovis or M. tuberculosis has been
shown to be associated with a TH1 immune response; gener-
ally characterized by production of cytokines such as IFN-,
IL-12, and TNF-. It would appear then that any successful
vaccine against tuberculosis would require the induction of
a TH1 immune response. The immune response to M. bovis
BCG has been investigated in white-tailed deer [9]. Upon
stimulation with M. bovis PPD, CD4+ and / T cells pro-
liferated in vaccinated but not unvaccinated deer. Likewise,
peripheral blood mononuclear cells (PBMC) from vaccinated
but not unvaccinated deer produced IFN- upon stimulation
with M. bovis PPD [9]. However, the ability of vaccination
with M. bovis BCG to protect against infection or disease
in white-tailed deer has not been explored. The purpose of
the current study was to determine the ability of parenterally
administered M. bovis BCG to prevent infection or disease
in white-tailed deer after intratonsilar challenge with virulent
M. bovis.
2. Materials and methods
2.1. Animals and bacteria
Thirty-one white-tailed deer (∼1 year old) were
obtained from a captive breeding herd (tuberculosis- and
paratuberculosis-free) at the National Animal Disease Center
(Ames, IA, USA). All deer were housed and cared for accord-
ing to institutional guidelines. Deer were randomly assigned
to one of three groups; 2 SC doses of 107 colony-forming
units (CFU) of M. bovis BCG administered 6 weeks apart
(n = 11); 1 SC dose of 107 CFU of M. bovis BCG (n = 10);
or unvaccinated deer (n = 10). The M. bovis BCG (Pasteur
strain) as well as the challenge strain M. bovis 1315 were
grown in Middlebrook’s 7H9 media supplemented with 10%
oleic acid–albumin–dextrose complex (Difco, Detroit, MI)
plus 0.05% Tween 80 (Sigma Chemical Co., St. Louis, MO)
as described [10]. Mid log-phase growth bacilli were pelleted
by centrifugation at 750 × g, washed twice with phosphate
buffered saline (PBS) (0.01 M, pH 7.2), and diluted to the
appropriate cell density in 2 ml of PBS. Bacilli were enumer-
ated by serial dilution plate counting on Middlebrook’s 7H11
selective media (Becton Dickinson, Cockeysville, MD). A
single vaccine dose consisted of 107 CFU M. bovis BCG
in 1.5 ml PBS and was administered SC. Individual vaccine
doses were thoroughly vortexed immediately prior to injec-
tion to disperse bacilli in suspension and minimize clumping.
In the 2 dose group a 6-week interval separated doses. Unvac-
cinated and vaccinated deer were housed together in an
outdoor paddock prior to challenge with virulent M. bovis, at
which time they were moved to appropriate biosecurity level
3 (BL-3) animal housing.
Seventy-seven days after the 2 dose group received the
second dose of vaccine all deer were inoculated intratonsi-
larly with approximately 150 CFU of M. bovis strain 1315
into each tonsilar crypt for a total dose of 300 CFU, as
described previously [11]. Strain 1315 was originally iso-
lated from a white-tailed deer in Michigan. For inoculation
deer were anesthetized by IM injection of a combination of
xylazine (2 mg/kg) (Mobay Corporation, Shawnee, KS) and
ketamine (6 mg/kg) (Fort Dodge Laboratories, Fort Dodge,
IA). After inoculation the effects of xylazine were reversed
by IV injection of tolazoline (4 mg/kg) (Lloyd Laboratories,
Shanandoah, IA). Animals were housed in BL-3 housing, and
fed a commercial pelleted feed with free access to water. All
procedures were approved by the National Animal Disease
Center Institutional Animal Care and Use Committee prior
to the beginning of the experiment.
2.2. Interferon-γ enzyme-linked immunosorbent assay
A whole-blood culture system for the determination of
recall IFN- production as used for cattle [12] and red deer
[13] was adapted for use with samples from white-tailed
deer [14]. Briefly, 1.5 ml heparinized blood was added to
24-well tissue culture plates. Treatments included 100 l
PBS (i.e., no stimulation), 20 g/ml M. bovis purified pro-
tein derivative (PPD), 20 g/ml M. avium PPD, 10 g/ml
rESAT-6:CFP-10, or 20 g/ml pokeweed mitogen (PWM).
Optimal dilutions of PPDs, recombinant proteins and PWM
were determined previously [14]. Samples were incubated for
48 h at 37 ◦C in a humidified chamber with 5% CO2. Samples
were then centrifuged (400 × g), and plasma was harvested
and stored at −80 ◦C until analyzed for IFN- by enzyme-
linked immunosorbent assay (ELISA) with a commercially
available kit (CervigamTM, Prionics AG, Schlieren, Switzer-
land). Interferon- concentrations (ng/ml) in test samples
were determined by comparing the absorbance of test sam-
ples with the absorbance of standards within a linear curve fit.
2.3. ELISA for antibody to lipoarabinomannan
(LAM)-enriched mycobacterial antigen preparations
Antigens were prepared from M. bovis strain 1315 and
antibody measured as described [15]. Bacilli were harvested
from 4-week cultures, sonicated in PBS, further disrupted
with 0.1–0.15 mm diameter glass beads (Biospec Products,
Bartlesville, OK) in a bead beater (Biospec Products), cen-
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trifuged, filtered (0.22 m pore size), and digested in a
1-mg/ml proteinase K (Roche Molecular Biochemicals, Indi-
anapolis, IN) solution (50 M Tris, 1 mM CaCl2 buffer, pH
8.0) for 1 h at 50 ◦C. Protein concentrations were determined
(BioRad, Hercules, CA) and antigens were stored at −20 ◦C.
The antigen concentration used for ELISA was 40 g/ml.
Immulon II 96 well microtiter plates (Dynatech, Chantilly,
VA) were coated with 100-l/well antigen diluted in car-
bonate/bicarbonate coating buffer (pH 9.6). Antigen coated
plates, including control wells containing coating buffer
alone, were incubated for 15 h at 4 ◦C. Plates were washed
three times with 200 l/well containing 0.05% Tween 20 (i.e.,
PBST; Sigma), and blocked with 200 l/well commercial
milk diluent/blocking solution (Kirkegaard and Perry Labo-
ratories, Gaithersburg, MD). After incubation for 1 h at 37 ◦C
in the blocking solution, wells were washed nine times with
200 l/well PBST and test sera added to wells (100 l/well).
Test and control sera were determined by evaluation of the
reactivity of twofold serial dilutions ranging from 1:6 to 1:800
(volume of sera/volume of diluent ratio) with antigen. After
incubation for 20 h at 4 ◦C with diluted test sera, wells were
washed nine times with 200 l/well PBST and incubated for
1 h at 37 ◦C with 100 l/well horseradish peroxidase (HRP)-
conjugated anticervine immunoglobulin G (IgG) heavy and
light chains (Kirkegaard and Perry) diluted 1:500 in PBS plus
0.1% gelatin. Wells were washed nine times with 200 l/well
PBST and incubated for 4.5 min at room temperature with
100 l/well 3,3′,5,5′-tetramethylbenzidine. The reaction was
stopped by addition of 100 l/well 0.18 M sulfuric acid, and
the A450 of individual wells was measured with an auto-
mated ELISA plate reader (Molecular Devices, Menlo Park,
CA). Changes in optical density readings (OD) were calcu-
lated by subtracting the mean OD readings for wells receiving
coating buffer alone (two replicates) from the mean OD read-
ings for antigen coated wells (two replicates) receiving the
same serum sample.
2.4. Necropsy and tissue sampling
One hundred and thirty days after challenge with vir-
ulent M. bovis all deer were euthanized by IV sodium
pentobarbital. At necropsy, the following tissues or fluids
were collected and processed for isolation of M. bovis and
microscopic analysis as described [16]; palatine tonsil, lung,
liver, mandibular, parotid, medial retropharyngeal, tracheo-
bronchial, mediastinal, hepatic, mesenteric and prefemoral
lymph nodes. Tissues were processed for isolation of M.
bovis as previously described [17]. Isolates of M. bovis were
identified by colony morphology, growth, and biochemical
characteristics as well as by PCR.
Lymph nodes were cross-sectioned at 0.5 cm intervals
and examined. Each lung lobe was examined separately and
cross-sectioned at 0.5–1.0 cm intervals. Lungs and lymph
nodes were subjected to semi-quantitative scoring of gross
lesions adapted from Vordermeier et al. [18]. Lung lobes
(left cranial, left caudal, right cranial, right caudal, middle
and accessory) were subjected to the following scoring sys-
tem: (0) no visible lesions; (1) no external gross lesions, but
lesions seen upon slicing; (2) <5 gross lesions of <10 mm
in diameter; (3) >5 gross lesions of <10 mm in diameter;
(4) >1 distinct gross lesion of >10 mm in diameter; (5) coa-
lescing gross lesions. Scoring of lymph node gross lesions
was based on the following scoring system: (0) no visi-
ble lesions; (1) small focal lesion (1–2 mm in diameter);
(2) several small foci; (3) extensive lesions. Tissues col-
lected for microscopic analysis were fixed by immersion
in 10% neutral buffered formalin and included all tissues
collected for bacteriologic examination. For microscopic
examination, formalin-fixed tissues were processed by rou-
tine paraffin-embedment techniques, cut in 5 m sections
and stained with hematoxylin and eosin (HE). Adjacent sec-
tions were cut from samples containing lesions suggestive
of tuberculosis (caseonecrotic granulomata) and stained by
the Ziehl-Neelsen technique for identification of acid-fast
bacteria (AFB). Numbers of AFB were recorded for each
granuloma. Due to an inability to reliably enumerate large
numbers of AFB, granulomas with >200 AFB were recorded
as >200 AFB. Microscopic tuberculous lesions were staged
(I–IV) according to criteria adapted from that described by
Rhoades et al. [19]. Stage I (initial) granulomas were char-
acterized by accumulations of epithelioid macrophages with
low numbers of lymphocytes and neutrophils. Multinucleated
giant cells may be present but necrosis was absent. Acid-
fast bacilli, when present, were seen within macrophages or
multinucleated giant cells. Stage II (solid) granulomas were
characterized by accumulations of epithelioid macrophages
surrounded by a thin connective tissue capsule. Infiltrates of
neutrophils and lymphocytes may be present as well as mult-
inucleated giant cells. Necrosis when present was minimal.
Stage III (necrotic) granulomas were characterized by com-
plete fibrous encapsulation. Necrotic cores were surrounded
by a zone of epithelioid macrophages admixed with mult-
inucleated giant cells and lymphocytes. Stage IV (necrotic
and mineralized) granulomas were characterized by a thick
fibrous capsule surrounding irregular multicentric granulo-
mas with multiple necrotic cores. Necrotic cores contained
foci of dystrophic mineralization. Epithelioid macrophages
and multinucleated giant cells surrounded necrotic areas and
there were often moderate to marked infiltrates of lym-
phocytes. Acid-fast bacilli were often present in moderate
numbers and primarily located within the caseum of the
necrotic core.
Additionally, each animal was assigned to one of three
classifications according to the scheme by Griffin et al. [6]: (1)
uninfected animals with no gross or microscopic lesions and
from which M. bovis could not be isolated by bacteriological
culture from samples collected, (2) infected animals from
which M. bovis could be isolated by bacteriological culture,
but no gross or microscopic lesions were present, and (3)
diseased animals with gross or microscopic lesions consistent
with tuberculosis and from which M. bovis could be isolated
by bacteriological culture.
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2.5. PCR methods
PCR was used to confirm M. bovis infection and to dis-
tinguish M. bovis from M. bovis BCG Pasteur. Region of
difference 1 (RD1), while present in virulent M. bovis is
absent from M. bovis BCG [20]. The following primer pairs
were used to detect the presence or absence of the RD1
region using a method similar to that described by Talbot
et al. [21]; RD1-1 GTTCATGCTCGCGGACTAC, RD1-2
ATACATCGGTGACCCTTTGC and RD1-3 TAGGTTCG-
GTTACGCTGGTT. Primers RD1-1 and RD1-3 produce a
542 bp product from M. bovis BCG Pasteur while RD-2 and
RD-3 produce a 384 bp product from M. bovis.
Mycobacteria were transferred to 25 l of sterile TE using
a sterile-disposable inoculation loop. The bacterial suspen-
sion was heat inactivated by heating to 80 ◦C for 10 min,
vortexed, then heated for an additional 10 min. One micro-
liter of the bacterial preparation was added to the following
PCR master mix: 1× PCR reaction buffer with MgCl2 (Roche
Applied Science), 50 pM of each primer, 200 M of each
dNTP (PCR Nucleotide Mix, Roche Applied Science), 2 U
FastStart Taq (Roche Applied Science), 5 g BSA (Ambion,
Austin, TX) in a total reaction volume of 50 l. Touchdown
PCR was performed with an initial preheating step of 2 min
at 94 ◦C followed by denaturation at 94 ◦C for 45 s, anneal-
ing started at 65 ◦C for 1 min with a 1 ◦C decrease per cycle
followed by extension at 72 ◦C for 2 min, after the annealing
temperature reached 50 ◦C an additional 29 cycles were per-
formed. A final extension at 72 ◦C for 10 min was included.
Samples were analyzed by electrophoresis on 1.5% agarose
gel and visualized with ethidium bromide.
Isolates of acid-fast bacteria that were not identified by
PCR as virulent M. bovis or M. bovis BCG Pasteur were
further identified using 16S ribosomal DNA sequencing as
described previously [22]. Sequences were then identified
through the use of a mycobacterial species sequence database
[23].
2.6. Statistical analysis
Mean group values for lesion scores were compared using
one-way repeated measures analysis of variance (GraphPad
Prism, GraphPad Software, San Diego, CA). Differences
between means were then compared using the Bonfer-
onni method. Results of IFN- analysis and ELISA were
compared using one-way analysis of variance followed by
Tukey–Kramer multiple comparisons test using a commer-
cially available statistics program (InStat 2.00, GraphPad
Software). A p-value <0.05 was considered significant.
3. Results
Regardless of group the most common site for lesion
development was the medial retropharyngeal lymph node
(9 of 10 diseased deer). Pulmonary lesions were less com-
Table 1
Summary of gross lesions, microscopic lesions and bacteriological isolation
of Mycobacterium bovis from white-tailed deer vaccinated with M. bovis






Gross lesions 5/10 2/10 1/11
Microscopic lesions 6/10 4/10 3/11
Isolation of virulent M. bovis 5/10 3/10 5/11
Isolation of M. bovis BCG 1/10 4/10 3/11
Isolation of M. bovis BCG from
tissues with lesions
0/1 0/4 2/3a
Isolation of M. bovis BCG only





Deer from which virulent M.
bovis was not isolated and
lesions were not seen
4/10 7/10 6/11




mon, being present in 4 of 10 diseased deer. Six of 10 (60%)
unvaccinated deer developed gross or microscopic lesions
consistent with tuberculosis (Table 1) and would be catego-
rized as diseased while 2/10 (20%) and 2/11 (18%) of M.
bovis BCG vaccinated deer were categorized as diseased in
the 1 dose and 2 dose groups, respectively.
Gross lesion severity scores of the medial retropharyn-
geal lymph node were significantly reduced in deer receiving
2 doses of M. bovis BCG compared to unvaccinated deer
(Fig. 1) but not significantly different compared to deer
receiving a single dose of BCG. Lesion severity scores of the
lungs did not differ between groups (data not shown). Total
pathology scores (sum of scores for lymph nodes and lung)
were lower (p = 0.1) in deer receiving 2 doses of BCG (Fig. 2)
compared to unvaccinated deer or deer receiving a single dose
of BCG. Microscopic evaluation of the medial retropharyn-
geal lymph nodes revealed a greater number of granulomas in
unvaccinated deer than in vaccinated deer (Table 2). All deer,
regardless of vaccination status, had microscopic lesions in
all stages. However, vaccinated deer had fewer stage IV gran-
ulomas than unvaccinated deer. Enumeration of AFB within
granulomas revealed that stage IV granulomas had a mean of
>200 AFB/granuloma while those of stages I–III had a mean
of 0–11 AFB/granuloma (Table 3).
Table 2
Numbers of granulomas at different microscopic stages of developmenta in
the medial retropharyngeal lymph node of white-tailed deer vaccinated with
M. bovis BCG and challenged by intratonsilar inoculation of 300 CFU of
virulent M. bovis
Stage I Stage II Stage III Stage IV Total
BCG 2 doses 2 3 5 1 11
BCG 1 dose 1 4 3 2 10
Unvaccinated 18 18 11 7 54
a Stages defined in text.
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Fig. 1. Gross lesion severity scores from medial retropharyngeal lymph
nodes of unvaccinated deer (n = 10) or deer vaccinated SC with one (n = 10)
or two doses (n = 11) of 107 CFU Mycobacterium bovis BCG Pasteur and
challenged intratonsilarly with 300 CFU of virulent M. bovis. Scores rep-
resent the mean ± standard error. Scoring system as follows: (0) no visible
lesions; (1) small focal lesion (1–2 mm in diameter); (2) several small foci;
(3) extensive lesions.
Fig. 2. Total combined gross lesion severity scores from lymph nodes and
lungs of unvaccinated deer (n = 10) or deer vaccinated SC with one (n = 10)
or two doses (n = 11) of 107 CFU M. bovis BCG Pasteur and challenged
intratonsilarly with 300 CFU of virulent M. bovis. Scores represent the
mean ± standard error. Scoring system as in Fig. 1 for lymph nodes. Lung
scoring system as follows: (0) no visible lesions; (1) no external gross lesions,
but lesions seen upon slicing; (2) <5 gross lesions of <10 mm in diameter;
(3) >5 gross lesions of <10 mm in diameter; (4) >1 distinct gross lesion of
>10 mm in diameter; (5) coalescing gross lesions.
Virulent M. bovis was isolated from 4 deer with no gross
or microscopic lesions (i.e. infected deer). Infected, but not
diseased deer included 1 deer from the 1 dose group and 3
deer from the 2 dose group. Uninfected deer (deer from which
virulent M. bovis could not be recovered and in which no gross
or microscopic lesions were seen) included 4 unvaccinated
deer, 7 deer from the 1 dose group and 6 deer from the 2 dose
group (Table 1).
Table 3
Mean number of AFB in medial retropharyngeal lymph node granulomas
of different developmental stagesa from white-tailed deer vaccinated with
M. bovis BCG and challenged by intratonsilar inoculation of 300 CFU of
virulent M. bovis
Stage I Stage II Stage III Stage IV
BCG 2 doses 1 0 5.4 >200b
BCG 1 dose 0 0 11.3 >200
Unvaccinated 0 0.17 0.18 >200
a Stages defined in text.
b Due to an inability to reliably enumerate large numbers of AFB, granu-
lomas with >200 AFB were recorded as >200 AFB.
M. bovis BCG was isolated at the time of necropsy from
8 deer, including 1 unvaccinated deer, 4 deer from the 1
dose group and 3 deer from the 2 dose group. Isolations
of BCG were made from various tissues including, medial
retropharyngeal, tracheobronchial, mediastinal and hepatic
lymph nodes. M. bovis BCG was isolated from a single site
in 5 deer, 2 sites in 2 deer and 3 sites in 1 deer. In 2 deer the
isolation of BCG was made from tissues (hepatic and medi-
astinal lymph nodes) in which microscopic, but not gross
lesions, were seen. In one of these 2 deer, virulent M. bovis
was also isolated from a microscopic lesion in the hepatic
lymph node. The mediastinal lymph node was the only tissue
from which BCG was isolated from the single unvaccinated
deer. In addition to virulent M. bovis and M. bovis BCG, M.
terrae and M. kansasii were isolated from 4 deer. In all cases
M. terrae was isolated from tissues not containing gross
or microscopic lesions. However, M. kansasii was isolated
from a mediastinal lymph node in which gross and micro-
scopic lesions were seen. Within that same animal, other
tissues contained lesions from which virulent M. bovis was
isolated.
Prior to challenge with virulent M. bovis, vaccinated
deer but not unvaccinated deer demonstrated IFN- produc-
tion in response to M. bovis PPD stimulation (Fig. 3A).
Although not statistically significant, deer receiving 2
doses of BCG had higher levels of IFN- produc-
tion after booster vaccination, than did deer receiving
1 dose of BCG. After intratonsilar challenge with viru-
lent M. bovis both vaccinated and unvaccinated deer were
shown to produce IFN- upon stimulation with M. bovis
PPD.
When rESAT-6:CFP-10 was used in place of M. bovis
PPD, neither vaccinated nor unvaccinated deer demonstrated
IFN- production prior to challenge with virulent M. bovis
(Fig. 3B). Similar to findings with M. bovis PPD, IFN-
production was evident in all groups in response to rESAT-
6:CFP-10 after challenge with virulent M. bovis. However,
in contrast to responses seen upon stimulation with M. bovis
PPD, IFN- production in response to rESAT-6:CFP-10 was
transient as levels returned to pre-challenge values by 80
days after challenge (220 days after vaccination). Prior to
initiation of the study all 3 deer from which M. terrae was
isolated did not show IFN- responses to M. bovis PPD, M.
avium PPD or rESAT-6:CFP-10. Following challenge, IFN-
responses were moderate to M. bovis PPD and rESAT-6:CFP-
10 compared to other deer in the same groups. The single deer
from which M. kansasii was isolated demonstrated moderate
IFN- responses to M. bovis PPD, M. avium PPD and rESAT-
6:CFP-10 prior to the study as well as following vaccination
and challenge.
Antibody responses to a LAM-enriched M. bovis antigen
were greater in vaccinated deer than in unvaccinated deer
(Fig. 4). Optical density values were significantly greater in
deer receiving 2 doses of BCG 63 and 112 and days after
primary vaccination compared to unvaccinated deer or deer
receiving a single dose of BCG. A significant boost in anti-
6594 M.V. Palmer et al. / Vaccine 25 (2007) 6589–6597
Fig. 3. Interferon- production in response to stimulation with M. bovis PPD
(A) or rESAT-6:CFP10 (B) as measured by optical density (OD, 450 nm).
Interferon- concentrations (ng/ml) in test samples were determined by com-
paring the absorbance of test samples with the absorbance of standards within
a linear curve fit. Samples from unvaccinated deer (n = 10) or deer vaccinated
with one (n = 10) or two doses (n = 11) of 107 CFU of M. bovis BCG were
analyzed for antigen specific IFN- production prior to and after vaccination
(day 0) and challenge with 300 CFU of virulent M. bovis (arrow, day 119).
Background OD values (stimulation with PBS alone) have been subtracted
from the response to M. bovis PPD or rESAT-6:CFP10. Data are represented
as means ± standard error.
body was not seen in vaccinated deer after challenge with
virulent M. bovis.
4. Discussion
Previous studies in red deer established that doses of
approximately 5 × 104 to 5 × 107 CFU of M. bovis BCG (Pas-
teur) provided protection against challenge with virulent M.
bovis [5,6]. These studies used intratonsilar challenge doses
of 100–500 CFU of virulent M. bovis similar to those used
in the present study. Also similar to findings in the current
study, two doses of BCG provided superior protection in red
deer compared to a single dose [6]. Although a single dose of
M. bovis BCG did not protect red deer against infection, it did
result in fewer animals with tuberculous lesions. The present
study design was patterned after extensive studies in red deer
that used a similar BCG strain with a similar interval between
priming and boosting doses of vaccine as well as a similar
interval between challenge and necropsy [5]. In those studies
Fig. 4. Response kinetics of serum antibody specific for LAM-enriched
antigen. Sera from unvaccinated deer (n = 10) or deer vaccinated with one
(n = 10) or two doses (n = 11) of 107 CFU of M. bovis BCG was analyzed for
reactivity to M. bovis derived LAM by ELISA prior to and after vaccination
(day 0) and challenge with 300 CFU of virulent M. bovis (arrow, day 119).
Data are represented as means ± standard error. *Significantly different from
unvaccinated deer (p < 0.05).
the interval from boosting dose to challenge and the interval
from challenge to necropsy did not decrease the protective
effect of vaccination. In contrast, the interval between prim-
ing and boosting doses of vaccine was critical as prolonged
intervals (i.e. 43 weeks) resulted in decreased protection [5].
The current findings are also in agreement with vaccination
studies in cattle, where vaccination with a similar dose of M.
bovis BCG (Pasteur) followed by intratracheal challenge with
virulent M. bovis resulted in less severe lesions in vaccinated
cattle compared to unvaccinated cattle [24]. In a separate
study, cattle dosed twice with M. bovis BCG demonstrated
fewer granulomas, less necrosis and fewer acid-fast bacilli
than unvaccinated cattle [25]. Studies to date in deer, and most
studies in cattle, have used BCG strain Pasteur. It is unknown
if other strains of BCG would differ in protective efficacy in
white-tailed deer compared to BCG Pasteur. Recently both
BCG strains Pasteur and Danish were reported to provide
similar levels of protection in vaccinated calves [26].
Similar to previous findings in white-tailed deer and red
deer, IFN- production in response to M. bovis PPD was
evident in vaccinated, but not unvaccinated deer. After vacci-
nation, no significant differences were seen in deer receiving
1 dose of M. bovis BCG compared to deer receiving 2
doses. IFN- production was not detected in vaccinated deer
prior to challenge when rESAT-6:CFP-10 was used as anti-
gen instead of M. bovis PPD. However, IFN- responses to
rESAT-6:CFP-10 responses were robust in all deer after chal-
lenge with virulent M. bovis, suggesting that responses to
rESAT-6:CFP-10 could prove useful in differentiating BCG
vaccinated from M. bovis infected deer. The lack of response
to rESAT-6:CFP-10 is due to the absence of the RD1 region
of the genome in M. bovis BCG compared to virulent M.
bovis. The genes responsible for ESAT-6 and CFP-10 produc-
tion are located within this RD1 region. The protein ESAT-6
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is co-secreted by members of the M. tuberculosis complex
in a tight 1:1 complex with CFP-10 [27]. Genes for both
ESAT-6 and CFP-10 are absent in many non-tuberculous
mycobacteria as well as the vaccine M. bovis BCG. However,
esat-6 and cfp-10 are present in a subset of non-tuberculous
mycobacteria such as M. kansasii, M. marinum, M. leprae
and M. smegmatis [28–30]. The presence of esat-6 and cfp-
10 in M. kansasii, likely explains the pre-vaccination and
pre-challenge response to rESAT-6:CFP-10 seen in the deer
from which M. kansasii was isolated. Lack of response to
these recombinant antigens by BCG vaccinated animals has
been proposed as a means of differentiating vaccinated from
infected animals [31,32] as well as differentiating M. bovis
infected animals from those infected with other mycobacte-
rial pathogens such as M. avium subsp. paratuberculosis [33].
Lipoarabinomannan is a cell wall glycolipid of mycobac-
teria. LAM-based ELISA assays, similar to that used in
the present study, have demonstrated utility for diagnosis
of mycobacterial diseases including bovine tuberculosis and
paratuberculosis [34,35].
Although the present study is the first to examine
the efficacy of BCG vaccination of white-tailed deer and
demonstrate some protection against challenge with vir-
ulent M. bovis, successful vaccination of wildlife poses
various challenges. It is doubtful that parenteral vaccina-
tion, such as that used in the present study, would be
feasible with free-ranging wildlife on a large scale. More
likely, an oral vaccine such as that currently used to vac-
cinate wildlife against rabies would be necessary [36].
Oral delivery of live BCG; while posing several chal-
lenges, has been shown to be feasible with white-tailed
deer [37]. Oral or intragastric vaccination of brushtail pos-
sums (Trichosurus vulpecula) with M. bovis BCG produces
inferior protection to intraduodenal vaccination [38–40].
However, lipid based preparations to protect live M. bovis
BCG from the harmful effects of the gastric environment
have proven effective in brushtail possum vaccination trials
[41].
In red deer, M. bovis BCG Pasteur was still present in tis-
sues from the site of injection as well as the draining lymph
nodes 3 months after SC vaccination with 2 × 106 CFU of
M. bovis BCG Pasteur [42]. Gross lesions in regional lymph
nodes and transmission from vaccinated deer to unvaccinated
deer have not been features of studies involving red deer
[43] or cattle. In the current study, unlike red deer, BCG
not only persisted in vaccinated deer, but spread to multi-
ple sites, was associated with microscopic granulomas, and
in one case, was shed by vaccinated deer and transmitted to
a unvaccinated deer, being recovered from the mediastinal
lymph node. Studies in mice demonstrate persistence of M.
bovis BCG for up to 30 weeks and spread to distant organs
after SC vaccination [44,45]. Murine studies further suggest
that persistence of M. bovis BCG within a vaccinated host
is vital in sustaining long-lasting immunological memory.
Vaccinated mice receiving chemotherapy to eliminate resid-
ual post-vaccinal BCG demonstrated inferior cell-mediated
immune responses and inferior protection against challenge
with virulent M. tuberculosis as measured by colonization of
the spleen by M. tuberculosis when compared to mice still
harboring low numbers of BCG [45,46]. Interestingly, per-
sistence of BCG has not been a feature of human vaccination
studies. Even among individuals with symptomatic AIDS,
bacteremia following BCG immunization is reported to be
uncommon [47]. However, recent analysis shows the risk of
disseminated disease from BCG vaccination may be signifi-
cantly greater in HIV infected infants compared to uninfected
infants [48].
Isolation of non-tuberculous mycobacteria from sev-
eral deer illustrates the challenges posed by exposure to
saprophytic non-tuberculous mycobacteria present in the
environment. Although exposure of red deer to environmen-
tal saprophytic mycobacteria did not influence susceptibility
to experimental infection with M. bovis [6], the low number
of deer similarly exposed in the present study precludes any
definitive conclusions; however, all 3 deer from which M.
terrae was isolated were categorized as uninfected while the
single deer from which M. kansasii was isolated was cat-
egorized as diseased. It is unclear from the current study
whether exposure to saprophytic environmental mycobac-
teria had a positive or negative effect on vaccine efficacy.
Studies in cattle have shown that sensitization of calves to
environmental saprophytic mycobacteria adversely affects
the protective efficacy of BCG vaccination [49]. Likewise,
one explanation for the highly variable, and often disap-
pointing, efficacy observed in human vaccine trials has been
exposure to saprophytic environmental mycobacteria [50].
Vaccination of neonatal calves has been used as a strategy
to avoid prior sensitization by saprophytic environmental
mycobacteria. Indeed, vaccination of neonatal calves induces
a higher level of immunity than that seen in calves vacci-
nated at 5–6 months of age [44,51–53]. A similar strategy
could be feasible for vaccination of captive white-tailed deer,
but would be problematic for vaccination of free-ranging
white-tailed deer. Although the ultimate goal of any tuber-
culosis vaccination program is to eradicate tuberculosis, a
more immediate aim is to reduce the rate of transmission
between susceptible hosts. Any tuberculosis vaccine con-
sidered for use in free-ranging white-tailed deer may not
need to protect animals against infection. Disease preva-
lence could be decreased if vaccinated animals did not
develop advanced lesions or shed virulent M. bovis, thereby
decreasing disease transmission. The present study demon-
strates that parenteral vaccination of white-tailed deer with
M. bovis BCG Pasteur provides some protection against
challenge with virulent M. bovis. The present study also
reveals several points that will require further investigation,
not least of which are those related to safety. Further stud-
ies will need to investigate the virulence of M. bovis BCG
in white-tailed deer and the degree and duration of vac-
cine persistence within tissues. Shedding of vaccine to other
deer or non-target species, including humans, also remains in
question.
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